Short Interest in UCB SA (OTCMKTS:UCBJY) Increases By 165.6%

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 8,500 shares, an increase of 165.6% from the May 15th total of 3,200 shares. Based on an average daily volume of 70,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

UCB Trading Down 0.5%

Shares of OTCMKTS:UCBJY traded down $0.51 on Monday, reaching $93.45. 52,630 shares of the company traded hands, compared to its average volume of 46,129. UCB has a fifty-two week low of $71.16 and a fifty-two week high of $106.60. The company's 50 day moving average is $87.48 and its 200-day moving average is $93.13. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Increases Dividend

The business also recently declared a dividend, which was paid on Wednesday, May 14th. Stockholders of record on Tuesday, April 29th were paid a $0.4838 dividend. The ex-dividend date of this dividend was Monday, April 28th. This is an increase from UCB's previous dividend of $0.46. This represents a dividend yield of 0.62%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.